Literature DB >> 10647084

Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis.

L Fattorini1, E Iona, M L Ricci, O F Thoresen, G Orrù, M R Oggioni, E Tortoli, C Piersimoni, P Chiaradonna, M Tronci, G Pozzi, G Orefici.   

Abstract

The in vitro activity of 16 antimicrobial agents against 46 drug-resistant strains of Mycobacterium tuberculosis recently isolated from Italian patients was determined. As for first-line antituberculosis drugs, while isoniazid was ineffective against all the strains tested, resistance to streptomycin, rifampicin, pyrazinamide, and ethambutol was 80.4%, 71.7%, 39.1%, and 8.7%, respectively. Among second-line antituberculous drugs, resistance to ciprofloxacin, ofloxacin, and sparfloxacin and to amikacin and kanamycin was around 20%. About 10% of the strains were resistant to capreomycin and cycloserine and 4.3% were resistant to ethionamide; no strain was found to be resistant to thiacetazone, para-aminosalicylic acid, and viomycin. Although all strains displayed a rather continuous distribution of minimal inhibitory concentrations (MICs), a bimodal distribution was observed for rifampicin, amikacin, and kanamicin, with very high MIC values for resistant strains; relatively low MICs were found for fluoroquinolone-resistant strains. Among the small number of strains resistant to second-line agents, low resistant levels were observed. Restriction fragment length polymorphism analysis showed few strain clusters with resistance to first-line antituberculous drugs and aminoglycosides, fluoroquinolones, or both. Altogether, these results showed that second-line agents were still active against the isoniazid-resistant and multiply first-line resistant strains tested, with none or low resistance levels; these observations can be of importance for the treatment of multidrug-resistant tuberculosis in Italy.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10647084     DOI: 10.1089/mdr.1999.5.265

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  10 in total

1.  Drug resistance evolution of a Mycobacterium tuberculosis strain from a noncompliant patient.

Authors:  Francesca Meacci; Germano Orrù; Elisabetta Iona; Federico Giannoni; Claudio Piersimoni; Gianni Pozzi; Lanfranco Fattorini; Marco R Oggioni
Journal:  J Clin Microbiol       Date:  2005-07       Impact factor: 5.948

2.  Impact of the E540V amino acid substitution in GyrB of Mycobacterium tuberculosis on quinolone resistance.

Authors:  Hyun Kim; Chie Nakajima; Kazumasa Yokoyama; Zeaur Rahim; Youn Uck Kim; Hiroki Oguri; Yasuhiko Suzuki
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

3.  Activities of drug combinations against Mycobacterium tuberculosis grown in aerobic and hypoxic acidic conditions.

Authors:  Giovanni Piccaro; Federico Giannoni; Perla Filippini; Alessandro Mustazzolu; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

4.  Evaluation of a new line probe assay for rapid identification of gyrA mutations in Mycobacterium tuberculosis.

Authors:  Federico Giannoni; Elisabetta Iona; Federica Sementilli; Lara Brunori; Manuela Pardini; Giovanni Battista Migliori; Graziella Orefici; Lanfranco Fattorini
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

5.  Unilamellar vesicles as potential capreomycin sulfate carriers: preparation and physicochemical characterization.

Authors:  Stefano Giovagnoli; Paolo Blasi; Claudia Vescovi; Giuseppe Fardella; Ione Chiappini; Luana Perioli; Maurizio Ricci; Carlo Rossi
Journal:  AAPS PharmSciTech       Date:  2004-12-31       Impact factor: 3.246

6.  Activities of moxifloxacin alone and in combination with other antimicrobial agents against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice.

Authors:  Lanfranco Fattorini; Dejiang Tan; Elisabetta Iona; Maurizio Mattei; Federico Giannoni; Lara Brunori; Simona Recchia; Graziella Orefici
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

7.  Multiplex PCR amplimer conformation analysis for rapid detection of gyrA mutations in fluoroquinolone-resistant Mycobacterium tuberculosis clinical isolates.

Authors:  Augustine F B Cheng; Wing W Yew; Edward W C Chan; Miu L Chin; Mamie M M Hui; Raphael C Y Chan
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

8.  Mechanism of thioamide drug action against tuberculosis and leprosy.

Authors:  Feng Wang; Robert Langley; Gulcin Gulten; Lynn G Dover; Gurdyal S Besra; William R Jacobs; James C Sacchettini
Journal:  J Exp Med       Date:  2007-01-16       Impact factor: 14.307

9.  Mutation EthAW21R confers co-resistance to prothionamide and ethionamide in both Mycobacterium bovis BCG and Mycobacterium tuberculosis H37Rv.

Authors:  Julius Mugweru; Jianxiong Liu; Gaelle Makafe; Gift Chiwala; Bangxing Wang; Changwei Wang; Xinjie Li; Yaoju Tan; Wing Wai Yew; Shouyong Tan; Tianyu Zhang
Journal:  Infect Drug Resist       Date:  2018-06-13       Impact factor: 4.003

Review 10.  A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis.

Authors:  Michael G Whitfield; Heidi M Soeters; Robin M Warren; Talita York; Samantha L Sampson; Elizabeth M Streicher; Paul D van Helden; Annelies van Rie
Journal:  PLoS One       Date:  2015-07-28       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.